US imposes 100% tariff on imported patented pharmaceuticals, impacting Australian exporters like CSL
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, targeting Australia’s largest exporter, CSL, which supplies about $1.3–$2 billion worth of drugs annually. The move aims to reshoring production to the US, offering reduced tariffs (20%) or exemptions for companies relocating factories or securing favorable drug pricing deals. Australia, which lacks a specific tariff exemption despite a long-standing free trade agreement, faces uncertainty for its exporters, though CSL may qualify for exemptions due to its US manufacturing plants and plasma-derived therapies. The Australian government has firmly rejected US pressure to alter its Pharmaceutical Benefits Scheme, which guarantees lower drug prices for Australians. Other countries like Japan, the EU, and the UK have negotiated lower tariffs (10–15%), highlighting Australia’s vulnerability. The tariff, enacted under Section 232 of trade law, bypasses a February Supreme Court ruling that struck down Trump’s broader 'Liberation Day' tariffs. While opposition leaders pledged to advocate for exemptions, the immediate impact includes heightened scrutiny for new medicine launches in Australia due to international pricing policies.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US on July 31, 2025 (ABC, SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- Australia exported approximately $1.32–$2 billion worth of pharmaceuticals to the US in 2024–2025 (NEWSCOMAU, ABC, GUARDIAN).
- CSL (ASX-listed biotech firm) is Australia’s largest pharmaceutical exporter to the US, with manufacturing plants in the US, Australia, and Europe (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- CSL announced a $1.5–$2.2 billion expansion of its US manufacturing facility in Kankakee, Illinois, set to complete by 2031 (SMH, NEWSCOMAU, GUARDIAN).
- The tariff applies to patented drugs only, excluding generic medicines (NEWSCOMAU, ABC).
- Companies moving production to the US can reduce tariffs to 20%, and those securing 'most favoured nation' drug pricing deals can avoid tariffs entirely (SMH, THEAGE, ABC, GUARDIAN).
- Australia has a long-standing free trade agreement with the US but lacks a specific pharmaceutical tariff exemption (SMH, THEAGE, NEWSCOMAU).
- The tariff is enacted under Section 232 of the Trade Expansion Act, not presidential emergency powers, so it is unaffected by the Supreme Court’s February 2025 ruling (SMH, ABC, NEWSCOMAU).
- Health Minister Mark Butler stated Australia will not negotiate changes to the Pharmaceutical Benefits Scheme (PBS) to accommodate US demands (SMH, THEAGE, NEWSCOMAU, GUARDIAN, ABC).
- Japan, EU, South Korea, Switzerland, and the UK have negotiated lower tariffs (10–15%) on pharmaceuticals (SMH, THEAGE, NEWSCOMAU, ABC).
- Large pharmaceutical companies have 120 days to announce re-shoring plans or face tariffs, while smaller firms get 180 days (SMH, ABC, GUARDIAN).
- CSL’s plasma-derived therapies (majority of its US exports) may qualify for exemptions if they meet urgent US health needs (SMH, THEAGE, NEWSCOMAU).
- Opposition Leader Angus Taylor pledged to work with the government to overturn or exempt Australian exporters from the tariffs (SMH, THEAGE, GUARDIAN, ABC)
Points of Difference
Details reported by only one source:
- A White House official explicitly stated 'Australia does not have a special pharma tariff rate' (noted in SMH only).
- The text of Trump’s executive order mentions tariffs would be zero for plasma-derived therapies if they come from a country with a 'current or forthcoming trade deal' with the US (SMH specifies this phrasing).
- The SMH article includes a quote from a White House official about CSL needing to submit its plan to the US Commerce Department for exemption discretion (not repeated elsewhere).
- SMH mentions Trump’s executive order reduces tariffs to 20% for companies moving production to the US *and* if the US receives 'most favoured nation' status in drug pricing (not explicitly paired in other sources).
- SMH notes the tariff adjustment for steel products (50% to 25% if >15% steel content) as part of broader tariff changes, which is not emphasized in other articles.
- TheAge does not include the specific $1.5 billion figure for CSL’s US expansion (only mentions 'a $US1.5 billion expansion' without the $2.17 billion AUD conversion).
- TheAge does not mention the 15% steel content threshold for tariff adjustments on steel products (only SMH covers this).
- NEWSCOMAU cites UN COMTRADE data for 2025 exports ($US1.32bn), while other sources use 2024 data or round figures ($1.3–$2bn).
- NEWSCOMAU explicitly states the tariff applies to patented products *not* generic medicines (not emphasized in other sources).
- NEWSCOMAU includes a direct quote from Health Minister Butler about 'uncertainty for exporters' and the government's 'clearest message' to the US about PBS (not verbatim in other sources).
- NEWSCOMAU mentions Medicines Australia’s statement about 'significant scrutiny' over new medicine launches due to low Australian prices (not covered elsewhere).
- NEWSCOMAU notes the tariff was invoked under 'national security powers' with a direct quote from Trump (not present in other articles).
- The Guardian states Australia exports about $2bn worth of drugs to the US annually (higher than other sources' $1.3–$1.9bn).
- The Guardian includes a quote from Communications Minister Anika Wells about the 'world-class quality' of Australian pharmaceuticals (not in other sources).
- The Guardian specifies the tariff was 'trying to force manufacturers to agree to drug-pricing deals or commit to making their products domestically' (not phrased this way elsewhere).
- ABC notes Trump previously said the tariff could be as high as 200% (not mentioned in other sources).
- ABC includes a direct quote from a senior administration official about 'drugs driven by research and development here in America' being produced abroad (not in other sources).
- ABC mentions the tariff was 'delayed' and Trump had 'flagged' it since 2024 (not emphasized in other sources).
- ABC states CSL's social media post in September 2024 suggested the tariff would take effect from October 2024 (not in other sources).
- SBS only provides a brief headline ('deeply disappointing and deeply concerning') without additional details (no unique facts).
Contradictions
Conflicting information between sources:
- NEWSCOMAU cites $US1.32bn in 2025 exports, while ABC and GUARDIAN cite $US1.3–$2bn in 2024 (no unified figure).
- SMH and THEAGE mention a $US1.5 billion expansion for CSL’s US facility, but NEWSCOMAU and GUARDIAN mention $US1.5–$2.2 billion (inconsistent figures).
- ABC states Trump previously said the tariff could be as high as 200%, but all other sources confirm the final rate is 100%.
- GUARDIAN states Australia exports $2bn annually, while SMH and THEAGE do not specify a total but focus on CSL’s dominance in exports.
- NEWSCOMAU mentions the tariff was invoked under 'national security powers' with a direct Trump quote, while other sources describe it as a 'trade' or 'Section 232' measure without this phrasing.
Source Articles
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....